MXPA03008904A - Composiciones de n-acetilcisteina y metodos para el tratamiento y prevencion de toxicidad de farmaco. - Google Patents
Composiciones de n-acetilcisteina y metodos para el tratamiento y prevencion de toxicidad de farmaco.Info
- Publication number
- MXPA03008904A MXPA03008904A MXPA03008904A MXPA03008904A MXPA03008904A MX PA03008904 A MXPA03008904 A MX PA03008904A MX PA03008904 A MXPA03008904 A MX PA03008904A MX PA03008904 A MXPA03008904 A MX PA03008904A MX PA03008904 A MXPA03008904 A MX PA03008904A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic
- acetylcysteine
- combination
- acetaminophen
- amount
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title claims abstract description 125
- 229960004308 acetylcysteine Drugs 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 64
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title description 12
- 206010070863 Toxicity to various agents Diseases 0.000 title description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 99
- 239000003814 drug Substances 0.000 claims abstract description 65
- 231100000419 toxicity Toxicity 0.000 claims abstract description 65
- 230000001988 toxicity Effects 0.000 claims abstract description 65
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 50
- 229960003180 glutathione Drugs 0.000 claims abstract description 49
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 48
- 108010024636 Glutathione Proteins 0.000 claims abstract description 45
- 230000001603 reducing effect Effects 0.000 claims abstract description 38
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000018417 cysteine Nutrition 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000036542 oxidative stress Effects 0.000 claims abstract description 19
- 231100000331 toxic Toxicity 0.000 claims abstract description 19
- 230000002588 toxic effect Effects 0.000 claims abstract description 19
- 230000008901 benefit Effects 0.000 claims abstract description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 198
- 229960005489 paracetamol Drugs 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000002221 antipyretic Substances 0.000 claims description 20
- 230000001754 anti-pyretic effect Effects 0.000 claims description 18
- 230000000202 analgesic effect Effects 0.000 claims description 16
- 230000003115 biocidal effect Effects 0.000 claims description 16
- 239000003443 antiviral agent Substances 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 11
- 206010037660 Pyrexia Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229940124522 antiretrovirals Drugs 0.000 claims description 8
- 239000003903 antiretrovirus agent Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 abstract description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 35
- 229960002555 zidovudine Drugs 0.000 description 35
- 238000009472 formulation Methods 0.000 description 26
- 229940079593 drug Drugs 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 10
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- URNSECGXFRDEDC-UHFFFAOYSA-N N-acetyl-1,4-benzoquinone imine Chemical compound CC(=O)N=C1C=CC(=O)C=C1 URNSECGXFRDEDC-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000007938 effervescent tablet Substances 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033296 Overdoses Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- -1 sulfhydryl compound Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000003870 Drug Overdose Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 231100000725 drug overdose Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SQOKHAVRKOFRLK-RGMNGODLSA-N C(C)NC=1NC=C(C[C@H](N)C(=O)O)N1.C(C)O Chemical compound C(C)NC=1NC=C(C[C@H](N)C(=O)O)N1.C(C)O SQOKHAVRKOFRLK-RGMNGODLSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001669680 Dormitator maculatus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010022523 Intentional overdose Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical class C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000133 toxic exposure Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28060001P | 2001-03-30 | 2001-03-30 | |
| US09/833,228 US6566401B2 (en) | 2001-03-30 | 2001-04-11 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| PCT/US2002/009442 WO2002078627A2 (en) | 2001-03-30 | 2002-03-28 | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03008904A true MXPA03008904A (es) | 2005-03-07 |
Family
ID=26960383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03008904A MXPA03008904A (es) | 2001-03-30 | 2002-03-28 | Composiciones de n-acetilcisteina y metodos para el tratamiento y prevencion de toxicidad de farmaco. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6566401B2 (enExample) |
| EP (1) | EP1379232B1 (enExample) |
| JP (3) | JP2005508840A (enExample) |
| CN (1) | CN100464743C (enExample) |
| AU (1) | AU2002255942B2 (enExample) |
| BR (1) | BR0208563A (enExample) |
| CA (1) | CA2442168C (enExample) |
| ES (1) | ES2550094T3 (enExample) |
| IL (2) | IL158181A0 (enExample) |
| MX (1) | MXPA03008904A (enExample) |
| NZ (1) | NZ528478A (enExample) |
| RU (1) | RU2291689C2 (enExample) |
| WO (1) | WO2002078627A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662863B2 (en) * | 2003-06-09 | 2010-02-16 | Alan Andrews | Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion |
| EP3753561A1 (en) | 2005-04-05 | 2020-12-23 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| RU2302236C2 (ru) * | 2005-09-09 | 2007-07-10 | Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) | Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции |
| US20070098790A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN102088965B (zh) * | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| US8575217B2 (en) * | 2009-03-16 | 2013-11-05 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| WO2010132864A1 (en) * | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| WO2011006097A2 (en) * | 2009-07-10 | 2011-01-13 | The Brigham And Women's Hospital, Inc. | Methods For Treating Toxicity |
| CA2767833C (en) * | 2009-07-15 | 2018-10-23 | Leland Stanford, The Board Of Trustees Of The Junior University | N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen |
| DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| US20140135396A1 (en) * | 2011-07-05 | 2014-05-15 | Beth Israel Deaconess Medical Center, Inc. | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide |
| US8747894B2 (en) | 2012-05-08 | 2014-06-10 | Alpex Pharma S.A. | Effervescent compositions containing N-acetylcysteine |
| WO2013175479A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity |
| SMT202200094T1 (it) | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
| EP3250196A4 (en) * | 2015-01-27 | 2018-09-26 | Florengale, LLC | Healing topical composition |
| JP2018524287A (ja) * | 2015-05-27 | 2018-08-30 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 造影後の膵炎のリスクを低下させるための組成物及び方法 |
| CN115957294A (zh) | 2015-05-28 | 2023-04-14 | 贝勒医学院 | 补充n-乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果 |
| WO2017122120A1 (en) * | 2016-01-11 | 2017-07-20 | Pledpharma Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| SMT202100404T1 (it) | 2016-02-04 | 2021-09-14 | Czap Research And Development Llc | Veicoli di complessi di inclusione di ciclodestrine stratificati e rilascio controllato |
| AU2017376391B2 (en) | 2016-12-15 | 2023-06-01 | Zambon S.P.A. | N-acetylcysteine for use as antibacterial agent |
| US11040007B2 (en) * | 2017-01-24 | 2021-06-22 | Woosung Pharmaceutical Co., Ltd. | Injection composition containing acetaminophen |
| EP3901620A4 (en) * | 2018-12-21 | 2022-02-16 | FUJIFILM Corporation | Phototoxicity or photoallergy measurement method and reagent for use in said measurement method |
| US11590090B2 (en) | 2019-09-14 | 2023-02-28 | Anzen Pharmaceuticals, LLC | Acetaminophen formulation with protection against toxic effects of overdose |
| GB2588172B (en) * | 2019-10-11 | 2023-05-24 | Blackhawk Partners Ltd | A pharmaceutical composition comprising cannabinoid |
| CN113288890B (zh) * | 2021-06-21 | 2022-02-22 | 南方医科大学南方医院 | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 |
| US12357667B2 (en) | 2021-07-28 | 2025-07-15 | Pono Lifestyle, Llc | Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins |
| EP4238559A1 (en) | 2022-03-04 | 2023-09-06 | Centre Hospitalier Universitaire de Caen Normandie | Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US547457A (en) * | 1895-10-08 | Trolley-track | ||
| IT1141406B (it) * | 1980-04-01 | 1986-10-01 | Dob Far Spa | Sali della cefapirina con aminoacidi |
| FR2519988B1 (fr) * | 1982-01-20 | 1985-06-14 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
| DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
| CA1339256C (en) * | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
| IT1248995B (it) * | 1990-06-26 | 1995-02-11 | Italfarmaco Spa | Composizioni farmaceutiche a base di sali ferrosi |
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
| US5475757A (en) * | 1994-06-07 | 1995-12-12 | At&T Corp. | Secure data transmission method |
| AU4399396A (en) * | 1994-12-19 | 1996-07-10 | Russinsky Limited | Compounds |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| FR2744917B1 (fr) | 1996-02-16 | 1998-04-10 | Kouchner Gerard | Composition therapeutique a base d'acetaminophene |
| US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| US5962421A (en) * | 1996-05-16 | 1999-10-05 | Zambon, S.A. | Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases |
| EP1019034A2 (en) * | 1997-07-01 | 2000-07-19 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| EP1141318B1 (en) * | 1999-01-04 | 2006-07-05 | Innovata PLC | P450 / acetaminophen gdept for cancer treatment |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
-
2001
- 2001-04-11 US US09/833,228 patent/US6566401B2/en not_active Expired - Lifetime
-
2002
- 2002-03-28 JP JP2002576895A patent/JP2005508840A/ja active Pending
- 2002-03-28 BR BRPI0208563-1A patent/BR0208563A/pt not_active IP Right Cessation
- 2002-03-28 AU AU2002255942A patent/AU2002255942B2/en not_active Expired
- 2002-03-28 IL IL15818102A patent/IL158181A0/xx unknown
- 2002-03-28 EP EP02725376.4A patent/EP1379232B1/en not_active Revoked
- 2002-03-28 CA CA2442168A patent/CA2442168C/en not_active Expired - Lifetime
- 2002-03-28 WO PCT/US2002/009442 patent/WO2002078627A2/en not_active Ceased
- 2002-03-28 MX MXPA03008904A patent/MXPA03008904A/es active IP Right Grant
- 2002-03-28 CN CNB028077334A patent/CN100464743C/zh not_active Expired - Fee Related
- 2002-03-28 ES ES02725376.4T patent/ES2550094T3/es not_active Expired - Lifetime
- 2002-03-28 RU RU2003131876/15A patent/RU2291689C2/ru not_active IP Right Cessation
- 2002-03-28 NZ NZ528478A patent/NZ528478A/en not_active IP Right Cessation
- 2002-11-04 US US10/287,175 patent/US7723389B2/en not_active Expired - Fee Related
-
2003
- 2003-09-30 IL IL158181A patent/IL158181A/en active IP Right Grant
-
2011
- 2011-08-01 JP JP2011168224A patent/JP2011225610A/ja active Pending
-
2014
- 2014-10-06 JP JP2014205506A patent/JP2015078185A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL158181A (en) | 2012-04-30 |
| JP2011225610A (ja) | 2011-11-10 |
| AU2002255942B2 (en) | 2007-07-05 |
| RU2003131876A (ru) | 2005-04-10 |
| IL158181A0 (en) | 2004-03-28 |
| ES2550094T3 (es) | 2015-11-04 |
| US20020142991A1 (en) | 2002-10-03 |
| EP1379232A2 (en) | 2004-01-14 |
| WO2002078627A3 (en) | 2003-09-18 |
| JP2005508840A (ja) | 2005-04-07 |
| WO2002078627A2 (en) | 2002-10-10 |
| EP1379232B1 (en) | 2015-07-29 |
| US20030069311A1 (en) | 2003-04-10 |
| NZ528478A (en) | 2007-08-31 |
| CN1507350A (zh) | 2004-06-23 |
| RU2291689C2 (ru) | 2007-01-20 |
| US6566401B2 (en) | 2003-05-20 |
| CN100464743C (zh) | 2009-03-04 |
| JP2015078185A (ja) | 2015-04-23 |
| CA2442168C (en) | 2012-05-29 |
| BR0208563A (pt) | 2006-02-21 |
| EP1379232A4 (en) | 2008-04-23 |
| US7723389B2 (en) | 2010-05-25 |
| CA2442168A1 (en) | 2002-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6566401B2 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| AU2002255942A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| ES2214729T3 (es) | Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas. | |
| Caravati et al. | Pediatric cyanide intoxication and death from an acetonitrile-containing cosmetic | |
| WO1994008628A1 (en) | Prevention of acetaminophen overdose toxicity with organosulfur compounds | |
| JP2010180244A (ja) | 肝癌発生・進展抑制剤 | |
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| US5248697A (en) | Enhancement of glutathione levels with glutamine | |
| JP2004502728A (ja) | 薬学的化合物の還元体の治療的および予防的使用 | |
| CA2767833A1 (en) | N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen | |
| JP2003171271A (ja) | 耐糖能異常用薬剤 | |
| RU2003122061A (ru) | Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl) | |
| US6048540A (en) | Acetamenophen composition with reduced liver toxicity | |
| SG186388A1 (en) | A combination composition comprising ibuprofen and paracetamol | |
| RU2372900C2 (ru) | Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с | |
| ZA200307559B (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity. | |
| US5670549A (en) | Prevention and amelioration of liver toxicity with beta-carotene | |
| US20050182136A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction | |
| Frye et al. | Pharmacology, formulations, and adverse effects | |
| JPS6354690B2 (enExample) | ||
| HO et al. | LEVOCARNITINE (L-CARNITINE)/CARNITOR MEDICATION PATIENT INFORMATION IN ENGLISH | |
| Frye et al. | and Adverse Effects | |
| HK1173336A (en) | N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen | |
| BR102012016109B1 (pt) | composição farmacêutica para controle de vaso-oclusão e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |